跳转至内容
Merck
CN
  • Decreased expression and prognostic role of cytoplasmic BRSK1 in human breast carcinoma: correlation with Jab1 stability and PI3K/Akt pathway.

Decreased expression and prognostic role of cytoplasmic BRSK1 in human breast carcinoma: correlation with Jab1 stability and PI3K/Akt pathway.

Experimental and molecular pathology (2014-07-19)
Hua Wang, Xiao-Bing Liu, Jia-Hui Chen, Qing-Qing Wang, Jin-Peng Chen, Jun-Fei Xu, Chen-Yi Sheng, Qi-Chao Ni
摘要

Jun activation domain-binding protein 1 (Jab1) was overexpressed in breast cancer, which was involved in degradation of the cyclin-dependent kinase inhibitor p27(Kip1). The objective of this study was to examine the effect of brain specific kinase 1 (BRSK1) expression on Jab1 over-expression and related signaling pathway in breast cancer. Immunohistochemical analysis was performed in 95 human breast carcinoma samples and the data were correlated with clinicopathologic features. Furthermore, Western blot analysis was performed for BRSK1 and Jab1 in breast carcinoma samples and cell lines to evaluate their protein levels and molecular interaction. We found that the cytoplasmic BRSK1 expression was inversely associated with Jab1 expression (P<0.01) and correlated significantly with histologic grade (P=0.006), however nuclear BRSK1 expression couldn't obtain similar results. Kaplan-Meier analysis revealed that survival curves of low versus high expressers of cytoplasmic BRSK1 and Jab1 showed a highly significant separation in breast cancer (P<0.01). While in vitro, following release of breast cancer cell lines from serum starvation, the expression of Jab1, phosphor-Akt (p-Akt) was up-regulated, whereas BRSK1 and p27(Kip1) were decreased. Treatment of phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 could diminish Jab1 expression but increase BRSK1 expression. In addition, we employed siRNA technique to knock down Jab1 and/or BRSK1 expression and observed their effects on MDA-MB-231 cell growth. BRSK1 is a novel tumor suppressor in breast cancer which inversely correlated with Jab1 expression, may involve in the restoring Jab1-induced suppression of p27(Kip1) and may regulate cell cycle through the PI3K/Akt pathway.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
乙醇,Pure 200纯度, Molecular Biology
Sigma-Aldrich
纯乙醇, 200 proof, ACS reagent, ≥99.5%
Sigma-Aldrich
纯乙醇, 200 proof
Sigma-Aldrich
纯乙醇, 200 proof, meets USP testing specifications
Sigma-Aldrich
纯乙醇, 200 proof, anhydrous, ≥99.5%
Sigma-Aldrich
乙醇,Pure 190纯度, for molecular biology
Sigma-Aldrich
纯乙醇, 190 proof, ACS spectrophotometric grade, 95.0%
Sigma-Aldrich
酒精, BioUltra, Molecular Biology, ≥99.8%, (absolute alcohol, without additive, A15 o1)
Supelco
无水乙醇, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
纯乙醇, 190 proof, meets USP testing specifications
Sigma-Aldrich
酒精, purum, fine spirit, denaturated with 4.8% methanol, F25 METHYL1, ~96% (based on denaturant-free substance)
Supelco
酒精, standard for GC
Sigma-Aldrich
酒精, puriss. p.a., absolute, ≥99.8% (GC)
Supelco
Ethanol 溶液, certified reference material, 2000 μg/mL in methanol
Sigma-Aldrich
酒精, tested according to Ph. Eur.
Supelco
10% (v/v) 乙醇标准品, 10 % (v/v) in H2O, analytical standard
Sigma-Aldrich
80% v/v 乙醇固定液, suitable for fixing solution (blood films)
Sigma-Aldrich
纯乙醇, 190 proof, ACS reagent, meets USP testing specifications, Excise Tax-free, Permit for use required
Sigma-Aldrich
纯乙醇, 200 proof, ACS reagent, meets USP testing specifications, Excise Tax-free, Permit for use required
Sigma-Aldrich
酒精, absolute, sales not in Germany, ≥99.8% (vol.)
Sigma-Aldrich
纯乙醇, 160 proof, Excise Tax-free, Permit for use required
Sigma-Aldrich
MISSION® esiRNA, targeting human BRSK1